Search Results - "Mrad, Chebli"

Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States by Singh, Abhay, Herr, Megan M., Griffiths, Elizabeth A., Przespolewski, Amanda, Faber, Mark G., Mrad, Chebli, Wang, Eunice S., Hahn, Theresa, Thota, Swapna

“…Clonal hematopoiesis (CH) is a risk factor for the development of therapy-related myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML). Adoption…”
Get full text

Trends in aggressive inpatient care at the end-of-life for stage IV lung cancer patients by Mrad, Chebli, Abougergi, Marwan S, Daly, Robert Michael

“…Abstract only 26 Background: Metastatic lung cancer patients are treated with palliative intent. Aggressive inpatient care at the end-of-life is seen as a…”
Get full text

Evolving risk of therapy-related myelodysplastic syndromes and acute myeloid leukemia (tMDS/AML) following modern cancer therapies by Singh, Abhay, Mrad, Chebli, Faber, Mark G, Hahn, Theresa, Wang, Eunice S., Herr, Megan, Thota, Swapna

“…Abstract only 7516 Background: Data describing risks of tMDS/AML after targeted and immunotherapy (IO) agents are lacking. Melanoma (Mel) and renal cell…”
Get full text

The Impact of Obesity on Mortality and Other Outcomes in Patients With Nonvariceal Upper Gastrointestinal Hemorrhage in the United States by Abougergi, Marwan S, Peluso, Heather, Mrad, Chebli, Saltzman, John R

“…GOALS:To quantify in patients with nonvariceal upper gastrointestinal hemorrhage (NVUGIH) the relationship between obesity and mortality, disease severity,…”
Get full text

The Incidence, Risk Factors and Impact of 30-Day Readmission of Patients With Upper Gastrointestinal Hemorrhage on Mortality and Healthcare Resource Utilization: A Nationwide Analysis: 2017 Prgesidential Poster Award: 559 by Abougergi, Marwan, Peluso, Heather, Mrad, Chebli, Saltzman, John

Get full text

The Incidence, Risk Factors and Impact of 30-Day Readmission After Whipple Procedure for Pancreatic Cancer on Mortality and Healthcare Resource Utilization: A Nationwide Analysis: 46 by Peluso, Heather, Abougergi, Marwan, Mrad, Chebli, Jones, Wesley

Get full text

Clinical and pathological predictors of micrometastasis in marginal thickness melanoma by Yaghi, Marita, Bilani, Nadeem, Dominguez, Barbara, Jabbal, Iktej Singh, Rivera, Carlos, Liang, Hong, Benedetto, Paul X, Mrad, Chebli, Nahleh, Zeina A., Arteta-Bulos, Rafael

“…e21585 Background: Sentinel lymph node biopsy (SLNB) remains controversial in patients with localized marginal thickness melanoma (MTM). Nonetheless,…”
Get full text

Trends in aggressive care at the end-of-life for stage IV lung cancer patients by Mrad, Chebli, Abougergi, Marwan S, Daly, Robert Michael

“…Abstract only 6614 Background: Prior studies have demonstrated that high-intensity end-of-life care improves neither survival nor quality of life for cancer…”
Get full text

Cerebrovascular Accidents Among African American Adults with Sickle Cell Disease: A Nationwide Outcomes and Trend Analysis over Two Decades by Mrad, Chebli, Pathak, Priyadarshini, Abougergi, Marwan S, Glassberg, Jeffrey A., Cytryn, Lawrence

“…Introduction: With nearly half of individuals with sickle cell disease (SCD) surviving into the sixth decade of life, there is a need to examine the incidence,…”
Get full text

The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers by Sabari, Joshua K, Santini, Fernando C, Schram, Alison M, Bergagnini, Isabella, Chen, Ruqin, Mrad, Chebli, Lai, W Victoria, Arbour, Kathryn C, Drilon, Alexander

“…Brigatinib (AP26113) is a dimethylphosphine oxide group-containing tyrosine kinase inhibitor (TKI) constructed around a bisanilinopyrimidine scaffold with…”
Get full text

PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC) by Sabari, Joshua K., Montecalvo, Joseph, Chen, Ruqin, Dienstag, Jordan A., Mrad, Chebli, Bergagnini, Isabella, Lai, Wei-Chu Victoria, Arbour, Kathryn Cecilia, Shu, Catherine A., Hellmann, Matthew David, Riely, Gregory J., Kris, Mark G., Rudin, Charles M., Rekhtman, Natasha, Drilon, Alexander E.

“…Abstract only 8512 Background: MET exon 14 skipping alterations ( METΔ14) are present in 4% of NSCLCs. Response to MET inhibition has been observed in ongoing…”
Get full text

One Step Forward, Two Steps Back: Trends in Aggressive Inpatient Care at the End of Life for Patients With Stage IV Lung Cancer by Mrad, Chebli, Abougergi, Marwan S, Daly, Bobby

“…Patients with metastatic lung cancer are treated with palliative intent. Aggressive care at the end of life is a marker of poor-quality care. National trends…”
Get full text